Baseline MRI markers and clinical outcomes during anti-amyloid β therapy: A real-world study in a Japanese dementia center - 17/10/26
, Marina Saito a, Manami Maruko a, Kazuko Kamiyama b, Aya Nakano c, Emi Qian d, Teppei Okamura e, Daisuke Ito d, f, Toshimi Kageyama g, Ichiro Sugiyama h, Eriko Ishihara h, Tatsuro Kuwahara i, Kazunori Moritani g, Hitoshi Katai j, Hidenori Hattori a
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | 161 consecutive patients treated with lecanemab or donanemab in routine care. |
• | Severe medial temporal atrophy predicted 12-month CDR-SB worsening with lecanemab. |
• | These patients were older and had poorer memory at a similar MMSE total score. |
• | Any baseline microbleed raised ARIA-H risk 14-fold within eligibility limits. |
• | Amyloid PET burden appeared to have no association in this cohort. |
ABSTRACT |
IMPORTANCE |
Predictors of decline and of amyloid-related imaging abnormalities (ARIA) during anti-amyloid β therapy in routine care are undefined.
OBJECTIVE |
To identify baseline predictors of cognitive, functional, and safety outcomes.
DESIGN, SETTING, AND PARTICIPANTS |
Retrospective cohort of 161 consecutive patients initiating anti-amyloid β therapy at a Tokyo dementia center, 2024 to 2026 (lecanemab, 89; donanemab, 72).
EXPOSURES |
Lecanemab or donanemab.
MAIN OUTCOMES AND MEASURES |
Change in MMSE and CDR-Sum of Boxes (CDR-SB); baseline medial temporal atrophy (VSRAD Z score), amyloid PET burden, and microbleeds; ARIA.
RESULTS |
With lecanemab, MMSE and CDR-SB declined significantly at every assessment (CDR-SB +0.79, +1.10, +1.60 at 6, 12, 18 months); memory and orientation declined while language was preserved. Greater baseline medial temporal atrophy was associated with greater 12-month CDR-SB worsening (r = 0.39; P = .01; n = 40); patients in the most severe standard category (Z ≥ 3) worsened by 2.62 versus 0.64 points (adjusted β = +2.18; P < .001). Atrophy was associated with older age (r = 0.19; P = .03) and with baseline memory-related measures — ADAS-Cog score (r = 0.32; P < .001) and the MMSE subdomains of delayed recall (β = −0.25; P = .006) and time orientation (β = −0.30; P = .04) — but not MMSE total score. Amyloid PET burden showed no significant association at most time points. All ARIA events were asymptomatic; ARIA-H occurred in 6 of 25 with microbleeds versus 3 of 136 without (odds ratio, 14.0; P < .001). Donanemab follow-up was 6 months.
CONCLUSIONS AND RELEVANCE |
Baseline medial temporal atrophy was associated with functional decline and microbleeds with ARIA-H. Pretreatment MRI may provide prognostic and safety information during anti-amyloid β therapy.
Le texte complet de cet article est disponible en PDF.Key Words : Alzheimer disease, Lecanemab, Donanemab, Medial temporal atrophy, Cerebral microbleeds, Amyloid-related imaging abnormalities
Plan
Vol 13 - N° 10
Article 100686- décembre 2026 Retour au numéro
Article précédent
- Updated Italian intersocietal recommendations for the appropriate use of anti-amyloid monoclonal antibodies in Alzheimer's disease
- Alberto Benussi, Federica Agosta, Luisa Agnello, Alba Rosa Alfano, Mattia Altini, Antonio Antico, Stefania Basilico, Giuseppe Bellelli, Laura Bonanni, Gabriella Bottini, Marco Bozzali, Ovidio Brignoli, Giuseppe Bruno, Annachiara Cagnin, Sonia Francesca Calloni, Stefano F. Cappa, Filippo Caraci, Diego Cecchin, Marcello Ciaccio, Sirio Cocozza, Mirco Cosottini, Diego De Leo, Andrea Falini, Lorenzo Gaetani, Nicoletta Gandolfo, Fabio Gotta, Raffaele Lodi, Giancarlo Logroscino, Elena Marcello, Camillo Marra, Walter Marrocco, Silvia Morbelli, Patrizia Mecocci, Enrico Mossello, Lorenzo Palleschi, Pasquale Palumbo, Leonardo Pantoni, Lucilla Parnetti, Luca Roccatagliata, Sandro Sorbi, Patrizia Spadin, Alessandra Splendiani, Alessandro Tessitore, Andrea Ungar, Giuseppe Zappalà, Alessandro Padovani
- Cerebral microhemorrhage and cognition in preclinical Alzheimer’s disease
- Dobri Baldaranov, Shunran Wang, Rema Raman, Karin Ernstrom, Kejal Kantarci, Clifford R. Jack, Reisa A Sperling, Paul S Aisen, Michael S Rafii
Bienvenue sur EM-consulte, la référence des professionnels de santé.